167 related articles for article (PubMed ID: 37216396)
1. Vemurafenib combined with cladribine and cytarabine results in durable remission of pediatric BRAF V600E-positive LCH.
Evseev D; Osipova D; Kalinina I; Raykina E; Ignatova A; Lyudovskikh E; Baidildina D; Popov A; Zhogov V; Semchenkova A; Litvin E; Kotskaya N; Cherniak E; Voronin K; Burtsev E; Bronin G; Vlasova I; Purbueva B; Fink O; Pristanskova E; Dzhukaeva I; Erega E; Novichkova G; Maschan A; Maschan M
Blood Adv; 2023 Sep; 7(18):5246-5257. PubMed ID: 37216396
[TBL] [Abstract][Full Text] [Related]
2. Clinical and prognostic characteristics of 95 cases of Langerhans cell histiocytosis in children: a single-institute experience from 2013 to 2020.
Tang X; Gao J; Ma ZG; Guo X; Li Q; Wan Z; Sun JJ
Ann Med; 2021 Dec; 53(1):1537-1546. PubMed ID: 34459688
[TBL] [Abstract][Full Text] [Related]
3. Vemurafenib provides a rapid and robust clinical response in pediatric Langerhans cell histiocytosis with the BRAF V600E mutation but does not eliminate low-level minimal residual disease per ddPCR using cell-free circulating DNA.
Evseev D; Kalinina I; Raykina E; Osipova D; Abashidze Z; Ignatova A; Mitrofanova A; Maschan A; Novichkova G; Maschan M
Int J Hematol; 2021 Dec; 114(6):725-734. PubMed ID: 34383272
[TBL] [Abstract][Full Text] [Related]
4. Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study.
Donadieu J; Larabi IA; Tardieu M; Visser J; Hutter C; Sieni E; Kabbara N; Barkaoui M; Miron J; Chalard F; Milne P; Haroche J; Cohen F; Hélias-Rodzewicz Z; Simon N; Jehanne M; Kolenova A; Pagnier A; Aladjidi N; Schneider P; Plat G; Lutun A; Sonntagbauer A; Lehrnbecher T; Ferster A; Efremova V; Ahlmann M; Blanc L; Nicholson J; Lambilliote A; Boudiaf H; Lissat A; Svojgr K; Bernard F; Elitzur S; Golan M; Evseev D; Maschan M; Idbaih A; Slater O; Minkov M; Taly V; Collin M; Alvarez JC; Emile JF; Héritier S
J Clin Oncol; 2019 Nov; 37(31):2857-2865. PubMed ID: 31513482
[TBL] [Abstract][Full Text] [Related]
5. Circulating cell-free BRAF
Héritier S; Hélias-Rodzewicz Z; Lapillonne H; Terrones N; Garrigou S; Normand C; Barkaoui MA; Miron J; Plat G; Aladjidi N; Pagnier A; Deville A; Gillibert-Yvert M; Moshous D; Lefèvre-Utile A; Lutun A; Paillard C; Thomas C; Jeziorski E; Nizard P; Taly V; Emile JF; Donadieu J
Br J Haematol; 2017 Aug; 178(3):457-467. PubMed ID: 28444728
[TBL] [Abstract][Full Text] [Related]
6. Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study.
Diamond EL; Subbiah V; Lockhart AC; Blay JY; Puzanov I; Chau I; Raje NS; Wolf J; Erinjeri JP; Torrisi J; Lacouture M; Elez E; Martínez-Valle F; Durham B; Arcila ME; Ulaner G; Abdel-Wahab O; Pitcher B; Makrutzki M; Riehl T; Baselga J; Hyman DM
JAMA Oncol; 2018 Mar; 4(3):384-388. PubMed ID: 29188284
[TBL] [Abstract][Full Text] [Related]
7. Vemurafenib combined with chemotherapy achieved sustained remission in pediatric LCH: a multi-center observational study.
Lei J; Wang W; Lin D; Zhu C; Jia W; Weng W; Liu X; Ma Y; Wang Z; Yang L; He X; He Y; Li Y
J Cancer Res Clin Oncol; 2024 Jan; 150(1):12. PubMed ID: 38231288
[TBL] [Abstract][Full Text] [Related]
8. [Status of Langerhans cell histiocytosis in children and adults].
Kudo K
Rinsho Ketsueki; 2019; 60(9):1308-1316. PubMed ID: 31597857
[TBL] [Abstract][Full Text] [Related]
9. Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis: results of an international phase 2 study.
Donadieu J; Bernard F; van Noesel M; Barkaoui M; Bardet O; Mura R; Arico M; Piguet C; Gandemer V; Armari Alla C; Clausen N; Jeziorski E; Lambilliote A; Weitzman S; Henter JI; Van Den Bos C;
Blood; 2015 Sep; 126(12):1415-23. PubMed ID: 26194764
[TBL] [Abstract][Full Text] [Related]
10. Treatment of recurrent Langerhans cell histiocytosis in children with 2-chlorodeoxyadenosine.
Mottl H; Starý J; Chánová M; Nekolná M; Drahokoupilová E; Smelhaus V
Leuk Lymphoma; 2006 Sep; 47(9):1881-4. PubMed ID: 17065001
[TBL] [Abstract][Full Text] [Related]
11. Progress towards molecular-based management of childhood Langerhans cell histiocytosis.
Héritier S; Emile JF; Hélias-Rodzewicz Z; Donadieu J
Arch Pediatr; 2019 Jul; 26(5):301-307. PubMed ID: 31281037
[TBL] [Abstract][Full Text] [Related]
12. 2'-Chlorodeoxyadenosine (2-CdA) as salvage therapy for Langerhans cell histiocytosis (LCH). results of the LCH-S-98 protocol of the Histiocyte Society.
Weitzman S; Braier J; Donadieu J; Egeler RM; Grois N; Ladisch S; Pötschger U; Webb D; Whitlock J; Arceci RJ
Pediatr Blood Cancer; 2009 Dec; 53(7):1271-6. PubMed ID: 19731321
[TBL] [Abstract][Full Text] [Related]
13. Successful treatment of Langerhans cell histiocytosis in an infant with vemurafenib: a case report and literature review.
Li Q
J Dermatolog Treat; 2023 Dec; 34(1):2279901. PubMed ID: 37941458
[TBL] [Abstract][Full Text] [Related]
14. [Recurrent and Refractory Langerhans Cell Histiocytosis in Children Treated with the Combination of Cladribine and Cytarabine].
DU Y; Xiong H; Li H; Li JX; Tao F; Yang L; Lu WJ; Qi SS; Zhang LN
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Jun; 30(3):943-949. PubMed ID: 35680831
[TBL] [Abstract][Full Text] [Related]
15. Treatment of refractory Langerhans cell histiocytosis (LCH) with a combination of 2-chlorodeoxyadenosine and cytosine arabinoside.
Apollonsky N; Lipton JM
J Pediatr Hematol Oncol; 2009 Jan; 31(1):53-6. PubMed ID: 19125089
[TBL] [Abstract][Full Text] [Related]
16. 2-Chlorodeoxyadenosine (2-CDA) for the treatment of refractory or recurrent Langerhans cell histiocytosis (LCH) in pediatric patients.
Stine KC; Saylors RL; Williams LL; Becton DL
Med Pediatr Oncol; 1997 Oct; 29(4):288-92. PubMed ID: 9251735
[TBL] [Abstract][Full Text] [Related]
17. Cutaneous adverse events in children treated with vemurafenib for refractory BRAF
Tardieu M; Néron A; Duvert-Lehembre S; Amine Larabi I; Barkaoui M; Emile JF; Seigneurin A; Boralevi F; Donadieu J
Pediatr Blood Cancer; 2021 Sep; 68(9):e29140. PubMed ID: 34109735
[TBL] [Abstract][Full Text] [Related]
18. A circulating subset of BRAF
Poch R; Le Louet S; Hélias-Rodzewicz Z; Hachem N; Plat G; Barkaoui MA; Lapillonne H; Delhommeau F; Emile JF; Donadieu J; Héritier S
Br J Haematol; 2021 Aug; 194(4):745-749. PubMed ID: 34312844
[TBL] [Abstract][Full Text] [Related]
19. Effective rescue treatment with vemurafenib of an infant with high-risk Langerhans cell histiocytosis.
Gerbaux M; Diallo S; Dedeken L; Dangoisse C; Bott A; Heritier S; Salik D; Ferster A
Ann Dermatol Venereol; 2020 Nov; 147(11):782-785. PubMed ID: 32653217
[TBL] [Abstract][Full Text] [Related]
20. BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy.
Héritier S; Emile JF; Barkaoui MA; Thomas C; Fraitag S; Boudjemaa S; Renaud F; Moreau A; Peuchmaur M; Chassagne-Clément C; Dijoud F; Rigau V; Moshous D; Lambilliotte A; Mazingue F; Kebaili K; Miron J; Jeziorski E; Plat G; Aladjidi N; Ferster A; Pacquement H; Galambrun C; Brugières L; Leverger G; Mansuy L; Paillard C; Deville A; Armari-Alla C; Lutun A; Gillibert-Yvert M; Stephan JL; Cohen-Aubart F; Haroche J; Pellier I; Millot F; Lescoeur B; Gandemer V; Bodemer C; Lacave R; Hélias-Rodzewicz Z; Taly V; Geissmann F; Donadieu J
J Clin Oncol; 2016 Sep; 34(25):3023-30. PubMed ID: 27382093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
